TIL

Instil Bio, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.24
52-Week Range: $5.67 – $21.98
Market Cap: $48.97M
P/E (TTM): —
EPS (TTM): -4.43
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.46
PEG Ratio: —
Return on Equity: -25.33%
Return on Assets: -10.77%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 21.67
Debt/Equity: 0.81
Total Debt: $87.42M
Free Cash Flow: $81.81M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $66.71M

TIL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$141.06M	$39.60M	$11.84M	$24.74M
Selling, General & Admin	$62.23M	$47.55M	$44.21M	$27.22M
Operating Expenses	$203.29M	$87.16M	$56.05M	$51.96M
Operating Income	-$203.29M	-$87.16M	-$56.05M	-$51.96M
EBITDA	-$217.38M	-$147.12M	-$62.53M	-$65.80M
Pretax Income	-$225.25M	-$156.09M	-$74.14M	-$71.37M
Income Tax	-$2.07M	$0.00	—	—
Net Income	-$223.18M	-$156.09M	-$74.14M	-$71.37M
Diluted EPS	-34.40	-24.00	-11.39	-10.70
Diluted Shares	6.48M	6.50M	6.51M	6.67M

TIL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$43.72M	$9.20M	$8.80M	$6.64M
Receivables	—	—	—	$848.00K
Current Assets	$269.38M	$160.76M	$124.47M	$191.43M
Total Assets	$482.13M	$325.63M	$263.57M	$203.52M
Current Liabilities	$32.79M	$10.56M	$7.90M	$4.84M
Long-Term Debt	$72.35M	$81.43M	$84.19M	$84.81M
Total Debt	$79.90M	$86.05M	$86.89M	$85.18M
Total Liabilities	$118.52M	$99.80M	$94.13M	$89.66M
Retained Earnings	-$424.89M	-$580.98M	-$655.12M	-$726.49M
Shareholders' Equity	$363.61M	$225.83M	$169.44M	$113.87M
Working Capital	$236.59M	$150.20M	$116.57M	$186.59M
Net Debt	$28.63M	$72.23M	$75.38M	$78.17M

TIL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$180.16M	-$82.03M	-$55.70M	-$36.62M
Capital Expenditure	-$84.59M	-$20.66M	-$10.00M	-$10.00M
Free Cash Flow	-$264.75M	-$102.69M	-$65.70M	-$46.62M
Depreciation & Amortisation	$5.99M	$4.76M	$3.61M	$534.00K
Stock-Based Compensation	$30.44M	$18.17M	$17.26M	$8.69M
Investing Cash Flow	$114.54M	$41.13M	$53.97M	$25.48M
Financing Cash Flow	$71.89M	$8.08M	$1.75M	$7.29M
Net Change in Cash	$6.26M	-$32.82M	$33.00K	-$3.85M

TIL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.37M	$6.74M	$9.13M	$3.50M	$669.00K	$270.00K
Selling, General & Admin	$9.11M	$6.16M	$5.89M	$6.06M	$5.35M	$5.13M
Operating Expenses	$14.48M	$12.90M	$15.02M	$9.56M	$6.02M	$5.40M
Operating Income	-$14.48M	-$12.90M	-$15.02M	-$9.56M	-$6.02M	-$5.40M
EBITDA	-$26.82M	-$19.80M	-$11.99M	-$7.40M	-$2.83M	-$2.47M
Pretax Income	-$28.20M	-$21.39M	-$13.59M	-$8.19M	-$4.20M	-$4.30M
Net Income	-$28.20M	-$21.39M	-$13.59M	-$8.19M	-$4.20M	-$4.30M
Diluted EPS	-4.32	-3.24	-2.01	—	-0.62	-0.63
Diluted Shares	6.53M	6.60M	6.76M	—	6.78M	6.78M

TIL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$15.37M	$7.69M	$5.80M	$6.64M	$5.02M	$5.54M
Receivables	$924.00K	$805.00K	$843.00K	$848.00K	$28.00K	$26.00K
Current Assets	$219.26M	$207.39M	$196.26M	$191.43M	$188.30M	$71.61M
Total Assets	$237.45M	$230.99M	$211.77M	$203.52M	$200.43M	$197.71M
Current Liabilities	$7.23M	$13.85M	$5.70M	$4.84M	$4.72M	$3.31M
Long-Term Debt	$84.23M	$84.42M	$84.61M	$84.81M	$85.00M	$85.19M
Total Debt	$86.67M	$84.88M	$84.92M	$85.18M	$85.19M	$87.42M
Total Liabilities	$92.54M	$99.32M	$91.35M	$89.66M	$89.73M	$90.33M
Retained Earnings	-$683.32M	-$704.71M	-$718.30M	-$726.49M	-$730.69M	-$734.99M
Shareholders' Equity	$144.91M	$131.67M	$120.42M	$113.87M	$110.70M	$107.38M
Working Capital	$212.03M	$193.53M	$190.57M	$186.59M	$183.58M	$68.30M
Net Debt	$68.86M	$76.73M	$78.81M	$78.17M	$79.98M	$79.65M

TIL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$4.20M	-$14.79M	-$10.56M	-$7.08M	-$1.34M	-$4.64M
Free Cash Flow	-$4.20M	-$14.79M	-$20.56M	-$7.08M	-$1.34M	-$4.64M
Depreciation & Amortisation	$498.00K	$12.00K	$12.00K	$12.00K	$12.00K	$248.00K
Stock-Based Compensation	$3.50M	$1.82M	$1.77M	$1.61M	$985.00K	$1.04M
Investing Cash Flow	$9.61M	-$400.00K	$8.45M	$7.82M	-$317.00K	$5.29M
Financing Cash Flow	$232.00K	$6.68M	$378.00K	$0.00	$0.00	$0.00
Net Change in Cash	$5.65M	-$8.51M	-$1.73M	$742.00K	-$1.65M	$649.00K

Market Snapshot

About

Instil Bio, Inc. is a clinical-stage biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer treatment. The company focuses on engineering and manufacturing personalized cell therapies to treat solid tumors. Instil Bio advances multiple TIL therapy candidates through clinical trials targeting various cancer types.